BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sloop KW, Emmerson PJ, Statnick MA, Willard FS. The current state of GPCR-based drug discovery to treat metabolic disease. Br J Pharmacol 2018;175:4060-71. [PMID: 29394497 DOI: 10.1111/bph.14157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Darbalaei S, Chang RL, Zhou QT, Chen Y, Dai AT, Wang MW, Yang DH. Effects of site-directed mutagenesis of GLP-1 and glucagon receptors on signal transduction activated by dual and triple agonists. Acta Pharmacol Sin 2022. [PMID: 35953646 DOI: 10.1038/s41401-022-00962-y] [Reference Citation Analysis]
2 Samms RJ, Zhang G, He W, Ilkayeva O, Droz BA, Bauer SM, Stutsman C, Pirro V, Collins KA, Furber EC, Coskun T, Sloop KW, Brozinick JT, Newgard CB. Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue. Molecular Metabolism 2022. [DOI: 10.1016/j.molmet.2022.101550] [Reference Citation Analysis]
3 Raines R, Mcknight I, White H, Legg K, Lee C, Li W, Lee PHU, Shim JW. Drug-Targeted Genomes: Mutability of Ion Channels and GPCRs. Biomedicines 2022;10:594. [DOI: 10.3390/biomedicines10030594] [Reference Citation Analysis]
4 Conley JM, Sun H, Ayers KL, Zhu H, Chen R, Shen M, Hall MD, Ren H. Human GPR17 missense variants identified in metabolic disease patients have distinct downstream signaling profiles. J Biol Chem 2021;297:100881. [PMID: 34144038 DOI: 10.1016/j.jbc.2021.100881] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Hou T, Bian Y, McGuire T, Xie XQ. Integrated Multi-Class Classification and Prediction of GPCR Allosteric Modulators by Machine Learning Intelligence. Biomolecules 2021;11:870. [PMID: 34208096 DOI: 10.3390/biom11060870] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Lazim R, Suh D, Lee JW, Vu TNL, Yoon S, Choi S. Structural Characterization of Receptor-Receptor Interactions in the Allosteric Modulation of G Protein-Coupled Receptor (GPCR) Dimers. Int J Mol Sci 2021;22:3241. [PMID: 33810175 DOI: 10.3390/ijms22063241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Im H, Park JH, Im S, Han J, Kim K, Lee YH. Regulatory roles of G-protein coupled receptors in adipose tissue metabolism and their therapeutic potential. Arch Pharm Res 2021;44:133-45. [PMID: 33550564 DOI: 10.1007/s12272-021-01314-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Krzak G, Willis CM, Smith JA, Pluchino S, Peruzzotti-Jametti L. Succinate Receptor 1: An Emerging Regulator of Myeloid Cell Function in Inflammation. Trends Immunol 2021;42:45-58. [PMID: 33279412 DOI: 10.1016/j.it.2020.11.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
9 Song L, Barrett DG, Cox KL, Efanov AM, Syed SK, Tomandl D, Willard FS. A High-Throughput Assay for the Pancreatic Islet Beta-Cell Potassium Channel: Use in the Pharmacological Characterization of Insulin Secretagogues Identified from Phenotypic Screening. Assay Drug Dev Technol 2021;19:27-37. [PMID: 33164547 DOI: 10.1089/adt.2020.1011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Naz F, Arish M. GPCRs as an emerging host-directed therapeutic target against mycobacterial infection: From notion to reality. Br J Pharmacol 2020. [PMID: 33150959 DOI: 10.1111/bph.15315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Darbalaei S, Yuliantie E, Dai A, Chang R, Zhao P, Yang D, Wang M, Sexton PM, Wootten D. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochemical Pharmacology 2020;180:114150. [DOI: 10.1016/j.bcp.2020.114150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Gong J, Chen Y, Pu F, Sun P, He F, Zhang L, Li Y, Ma Z, Wang H. Understanding Membrane Protein Drug Targets in Computational Perspective. Curr Drug Targets 2019;20:551-64. [PMID: 30516106 DOI: 10.2174/1389450120666181204164721] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
13 Nakliang P, Lazim R, Chang H, Choi S. Multiscale Molecular Modeling in G Protein-Coupled Receptor (GPCR)-Ligand Studies. Biomolecules 2020;10:E631. [PMID: 32325877 DOI: 10.3390/biom10040631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang Y, Wang H, Zhu G, Qian A, Chen W. F2r negatively regulates osteoclastogenesis through inhibiting the Akt and NFκB signaling pathways. Int J Biol Sci 2020;16:1629-39. [PMID: 32226307 DOI: 10.7150/ijbs.41867] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Heifetz A, Morao I, Babu MM, James T, Southey MWY, Fedorov DG, Aldeghi M, Bodkin MJ, Townsend-Nicholson A. Characterizing Interhelical Interactions of G-Protein Coupled Receptors with the Fragment Molecular Orbital Method. J Chem Theory Comput 2020;16:2814-24. [PMID: 32096994 DOI: 10.1021/acs.jctc.9b01136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Willard FS, Ho JD, Sloop KW. Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology. Adv Pharmacol 2020;88:173-91. [PMID: 32416867 DOI: 10.1016/bs.apha.2020.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Wong RW, Balachandran A, Cheung PK, Cheng R, Pan Q, Stoilov P, Harrigan PR, Blencowe BJ, Branch DR, Cochrane A. An activator of G protein-coupled receptor and MEK1/2-ERK1/2 signaling inhibits HIV-1 replication by altering viral RNA processing. PLoS Pathog 2020;16:e1008307. [PMID: 32069328 DOI: 10.1371/journal.ppat.1008307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
18 Langmead CJ, Summers RJ. Molecular pharmacology of GPCRs. Br J Pharmacol 2018;175:4005-8. [PMID: 30302756 DOI: 10.1111/bph.14474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Eguchi A, Nakakido M, Nagatoishi S, Kuroda D, Tsumoto K, Nagamune T, Kawahara M. An epitope‐directed antibody affinity maturation system utilizing mammalian cell survival as readout. Biotechnology and Bioengineering 2019;116:1742-51. [DOI: 10.1002/bit.26965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhu X, Huang G, Jin P. Clinicopathological and prognostic significance of aberrant G protein-couple receptor 110 (GPR110) expression in gastric cancer. Pathol Res Pract 2019;215:539-45. [PMID: 30638950 DOI: 10.1016/j.prp.2018.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hoffmann TJ, Choquet H, Yin J, Banda Y, Kvale MN, Glymour M, Schaefer C, Risch N, Jorgenson E. A Large Multiethnic Genome-Wide Association Study of Adult Body Mass Index Identifies Novel Loci. Genetics 2018;210:499-515. [PMID: 30108127 DOI: 10.1534/genetics.118.301479] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
22 Sloop KW, Briere DA, Emmerson PJ, Willard FS. Beyond Glucagon-like Peptide-1: Is G-Protein Coupled Receptor Polypharmacology the Path Forward to Treating Metabolic Diseases? ACS Pharmacol Transl Sci 2018;1:3-11. [PMID: 32219200 DOI: 10.1021/acsptsci.8b00009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
23 Sloop KW, Emmerson PJ, Statnick MA, Willard FS. The current state of GPCR-based drug discovery to treat metabolic disease. Br J Pharmacol 2018;175:4060-71. [PMID: 29394497 DOI: 10.1111/bph.14157] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]